Compare Novavax Inc (NVAX) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Orion Office REIT Inc — how do they compare? Novavax Inc trades at $12.84 (market cap $1.82B), while Orion Office REIT Inc trades at $2.18 (market cap $125.50M). The key difference: Novavax Inc is far larger — about 14.5× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Orion Office REIT Inc for 33 Days on average.
| NVAX | ONL | |
|---|---|---|
Market Cap | $1.82B | $125.50M |
Volume | 6,198,505 | 303,276 |
Sector | Health | Real Estate |
52-Week High | $12.56 | $3.00 |
52-Week Low | $6.22 | $1.93 |
Typical Hold Time | 59 Days | 33 Days |
Enterprise Value | $1.39B | $542.43M |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
ONL trades at $2.20, down 3.08% with a bearish technical signal despite oscillators showing some bullish momentum. The company shows declining revenue from $208M in 2022 to $148M in 2025 with persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics show low P/S (0.88) and P/B (0.2) ratios, while analyst sentiment is split evenly between Buy and Hold recommendations.
The outlook remains challenging with ongoing revenue declines and negative profitability, though deep valuation discounts and strategic portfolio repositioning offer potential upside. Key risks include high debt levels, office sector headwinds, and execution challenges in turning around financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
